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Abstract
Background: Variants in the TCF7L2 have been shown to be associated with an increased risk for type 2 diabetes
(T2D). Since the association with diabetes could be explained by effects on insulin secretion, we investigated
whether patients with diabetes risk alleles at rs7903146 might have an altered hypoglycaemic response to
sulfonylureas (SUs).
Methods: We recruited 189 patients with T2D being treated with SUs and determined the rs7903146 diabetes risk
genotype. We used a logistic regression with secondary SU failure defined as an A1C ≥7.0% after 6 months of SU
treatment.
Results: In univariate regression analyses, TCF7L2 genotype was the only predictor of SU treatment failure. The
rs7903146 T allele was significantly more frequent in the group of patients who failed to respond to SU (36%) than
in the control group (26%) [P = 0.046; odds ratio (OR): 1.57 (1.01-2.45) in an additive mode of inheritance].
Conclusions: Our data suggest that patients with diabetes risk alleles in TCF7L2 have an altered hypoglycaemic
response to SUs resulting in earlier secondary failure.
Background
The TCF7L2-gene (TCF7L2; Transcription factor 7-like
2) encodes a transcription factor (Tcf-4) that is involved
in the regulation of cellular proliferation and differentia-
tion [1]. Variants in the TCF7L2 have initially been
shown to be associated with an increased risk for type 2
diabetes (T2D) in a genome-wide analysis of the isolate
population of Iceland [2]. The strongest associations
with T2D with a clear gene dose effect were reported
for the rs7903146 variant [3]. The initial findings have
been replicated in independent studies in multiple eth-
nic populations and were summarized in a large global
meta-analysis [4]. The risk alleles actually predicted the
progression from impaired glucose tolerance to diabetes
prospectively [5] and an increased severity of the disease
[6] in adults. Also, TCF7L2 variants conferred a higher
risk for early impairment of glucose metabolism emer-
ging as soon as in childhood and adolescence [7]. Some
clinical data suggested that the polymorphisms affected
the capacity of pancreatic b-cells to secrete insulin
rather than aggravating insulin resistance [5,8-13], possi-
bly by impaired b-cell proinsulin-processing [14]. This
was further supported by expression data suggesting a
putative role of TCF7L2 in b-cell differentiation [12].
Considering the role of TCF7L2 risk variants in insulin
secretion, Pearson et al. [15] hypothesized that patients
with diabetes risk alleles at rs12255372 and rs7903146
have an altered hypoglycaemic response to sulfonylureas
(SUs) due to decreased b-cell function. They could
indeed show that carriers of the diabetes risk alleles
from the GoDART (Genetics of Diabetes Audit and
Research Tayside) study were less likely to respond to
SUs [15]. This study suggested that genetic variation in
TCF7L2 can alter response to therapy in T2D. Since a
causal phenotype-genotype relationship can not be
established with one initial report, replication studies
are the backbone to the genetic epidemiology of com-
plex diseases [16], and play a crucial role in pharmaco-
genomics as well.
Therefore, we sought to evaluate the association
between genetic variants in TCF7L2 with SU treatment
failure in an independent cohort from Germany. We
recruited 189 patients with T2D being treated with SU
agents and determined the TCF7L2 rs7903146 diabetes
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strongest association with T2D [3]. We used a logistic
regression with secondary SU failure defined as an A1C
≥7.0% after 6 months of SU treatment.
Methods
Subjects
One hundred and eighty-nine patients with T2D, all of
them being treated with SU agents, were recruited at the
medical department of the Klinikum Lippe-Detmold, a
large tertiary care hospital in East Westphalia, Germany,
between 1 January 2000 and 30.11.2009. As the only hos-
pital in the area, the one at Lippe-Detmold is responsible
for the inpatient and outpatient management of all emer-
gencies in the region. All patients had been treated with
the SU drugs glimepiride (n = 147), glibenclamide (n =
39) and gliquidon (n = 3). Ninety-seven patients failed to
respond to SU treatment according to our definition of
A1C ≥7.0% after 6 months of treatment (76 patients trea-
ted with glimepiride, 19 with glibenclamide and 2 with
gliquidon). Forty six patients were additionally treated
with insulin. The mean (± SD) daily dose of SU agents
was comparable between subjects who failed to respond
to SUs and the controls (5.0 ± 3.7 mg vs. 6.8 ± 3.7 mg,
P =0 . 1 3f o rg l i b e n c l a m i d e ;2 . 5±1 . 6m gv s .2 . 5±1 . 4m g
for glimepiride, P = 0.99). As our patients were recruited
within the framework of a study originally investigating
the risk of hypoglycaemia [17], eighty nine patients had
experienced a severe hypoglycaemia, which was defined
as a symptomatic event requiring treatment with intrave-
nous glucose and was confirmed by a blood glucose mea-
surement of <50 mg/dl (<2.8 mmol/l). Seventy-two
subjects were additionally treated with insulin sensitizing
drug metformin (32 patients in the control group and
40 patients in the group of patients with SU treatment
failure; P = 0.36, Table 1). The protocol was approved by
the Ethics Committee of the University of Münster
School of Medicine and by the Ethics Committee of the
University of Leipzig, School of Medicine. All patients
gave written informed consent to participate in the study.
Genotyping of rs7903146
Genotyping of rs7903146 in all study subjects was done
using the TaqMan allelic discrimination assay (Assays-
on-Demand (TM), SNP Genotyping Products; Applied
Biosystems, Inc.) on an ABI PRISM 7500 sequence
detector (Applied Biosystems Inc.) according to the
manufacturer’s protocol. The genotype distribution was
consistent with Hardy-Weinberg equilibrium (P >0 . 0 5 ) .
Genotyping success rate was >99%, and duplicate geno-
typing concordance was 100%.
Statistics
Standard descriptive and comparative statistics (c
2 test,
t-test) were used to characterize and compare clinical
parameters in different groups (controls, cases). Logistic
regression analyses were used to calculate the effects of
investigated factors on SU treatment failure, which were
reported as odds ratio with 95% CI (confidence inter-
vals). In the additive model, homozygotes for the major
allele, heterozygotes and homozygotes for the minor
allele were coded to a continuous numeric variable for
genotype (as 0, 1, 2). Data were analyzed using the SPSS
software package (version 15.0; SPSS, Inc., Chicago, IL).
Results
Clinical characteristics of all study participants are given
in Table 1. As expected, the subjects with failure of SU
treatment had a higher A1C than the controls (Table 1).
However, both groups were comparable in regard to the
age, gender, age at onset of diabetes, duration of dia-
betes and creatinine clearance and co-medication
Table 1 Clinical characteristics of all participants
Treatment with sulfonylurea (A1C <7%) Failure of treatment with sulfonylurea (A1C≥7%) P-value
N=9 2 N=9 7
Gender (Male/Female) 45/47 47/50 0.95*
Age (yr) 78.2 ± 9.6 78.3 ± 9.0 0.98
BMI (kg/m
2) 26.8 ± 5.2 27.0 ± 4.7 0.71
Creatinine (mg/dl) 1.73 ± 1.20 1.52 ± 0.55 0.13
Creatinine clearence (ml/min) 42.96 ± 22.61 42.10 ± 18.77 0.79
A1C (%) 6.13 ± 0.51 7.65 ± 1.40 <0.001
Age at onset of diabetes (yr) 68.0 ± 13.4 66.0 ± 10.9 0.28
Diabetes duration (yr) 10.2 ± 9.5 11.9 ± 8.4 0.20
Co-medication (n all drugs) 7 ± 3 7 ± 3 0.29
Sulfonylurea daily dose (mg) 3.68 ± 6.40 4.24 ± 6.85 0.56
Metformin treatment (n patients) 32 40 0.36*
Data are mean ± SD; P- values for comparisons between genotypic groups by ANOVA statistics.
*- c
2 test.
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(Table 1). Also the number of patients additionally trea-
ted with metformin was similar between the groups
(Table 1).
I nt h eu n i v a r i a t el o g i s t i cr e g r e s s i o na n a l y s e s ,t h e
TCF7L2 genotype was the only predictor of SU treat-
ment failure (Table 2). The rs7903146 T allele was sig-
nificantly more frequent in the group of patients who
failed to respond to SU (36%) than in the control group
(26%) [P = 0.046; odds ratio (OR): 1.57 (1.01-2.45) in an
additive mode of inheritance] (Table 3). In the control
group, 56.0% of subjects had the CC, 36.3% had the CT
and 7.7% had the TT genotype. Among patients who
failed to respond to SUs, 41.2% were CC homozygous,
46.4% were CT heterozygous and 12.4% were TT homo-
zygous (Table 3).
To investigate whether the rs7903146 effect is specific
to the mechanism of action of SUs, we evaluated the
genotype effects on response to a non-insulin secretago-
gue metformin. By analysing 72 metformin-treated indi-
viduals only, no effect of the genotype on SU treatment
failure was found [P = 0.98; OR 1.01 (0.50-2.03)].
Secondary confirmatory analyses
In secondary analyses we used a logistic regression with
secondary SU failure defined as the addition of insulin
after at least 6 months of SU therapy and corresponding
A1C measurement of ≥7.0%. Based on these criteria 46
patients from our cohort failed to respond to SU treat-
ment and were additionally treated with insulin.
In the univariate logistic regression analyses including
46 patients who failed to respond to SU treatment and
143 control subjects, diabetes duration (<5 yrs vs.
>5 yrs) appeared to be the strongest predictor of SU
treatment failure [OR: 4.06 (1.50-11.01), P =0 . 0 0 6 ] .W e
also assessed the effect of rs7903146 on SU treatment
failure. The rs7903146 T allele was significantly more
frequent in the group of patients additionally treated
with insulin (40%) than in the control group treated
only with SUs (28%) [P = 0.03; odds ratio (OR): 1.73
(1.06-2.84) in an additive mode of inheritance]. In the
control group, 53% of subjects had the CC genotype,
39% had CT and 8% had TT. Among patients treated
with insulin, 35% were CC homozygous, 50% were CT
heterozygous and 15% had the TT genotype. The results
remained materially unchanged even after including dia-
betes duration as a strong predictor of SU treatment
failure in these analyses, thus indicating an independent
effect of the genotype [OR: 1.66 (0.99-2.79), P =0 . 0 6i n
additive model].
Discussion
In the present study, we investigated the effect of
TCF7L2 diabetes risk T-allele at rs7903146 on therapeu-
tic response to SUs. In univariate regression analyses,
TCF7L2 genotype was the only predictor of SU treat-
ment failure. The rs7903146 T-allele conferred a higher
risk for sulfonylurea treatment failure as it was signifi-
cantly more frequent in the group of patients who failed
to respond to SUs (36%) than in the control group
(26%). After adjusting for diabetes duration the odds
ratio did not change (OR = 1.57) and the P-value
reduced just minimally (from P = 0.046 to P = 0.057),
thus indicating independent effect of the TCF7L2 geno-
type. Despite the smaller sample size and so, limited sta-
tistical power, our data are in line with findings reported
by Pearson et al. [15], suggesting that variation in
TCF7L2 influences therapeutic response to SUs. Pearson
et al. observed that homozygous carriers of the TCF7L2
risk alleles (rs1225372 and rs7903146) were twice as
likely not to respond to SUs as patients homozygous for
the non-risk alleles [15]. Considering pretreatment A1C
levels as covariate in logistic regression analyses even
strengthened the association between sulfonylurea
response and genotype at rs7903146 [15]. Even though
the findings are consistent between the present study
and that reported by Pearson et al., several differences
should be noted. First, Pearson et al. investigated a total
of 911 SU users of 4,469 patients with T2D from the
DARTS/MEMO (Diabetes Audit and Research Tayside/
Medicines Monitoring Unit) collaboration database, who
were recruited to GoDARTS between 1997 and 2006
[15]. Second, SU failure was defined very restrictively as
an A1C >7% within 3-12 months after treatment initia-
tion. According to these criteria, 42% of SU users failed
to respond to the therapy [15]. In our study we chose a
comparable, overlapping definition of secondary SU fail-
u r ew i t ha tl e a s t6m o n t h so fS Ut h e r a p ya n dc o r r e -
sponding A1C measurement of ≥7.0%. According to this
definition, 51% of our patients failed to respond to SU
therapy. We are aware that the difference in SU treat-
ment failure frequency mayb ed u et ov a r i o u ss t u d y
designs but it is noteworthy that to date, there is no
widely accepted definition of secondary SU failure. Due
to the lack of uniform definition, the frequency of SU
Table 2 Univariate regression analyses of predictors on
failure of sulfonylurea treatment in patients with type 2
diabetes
Odds ratio (95% CI) P-value
Gender 0.98 (0.56-1.74) 0.95
Age (yr) 1.00 (0.97-1.03) 0.98
Diabetes duration (<5 yrs vs.
>5 yrs)
1.65 (0.86-3.17) 0.13
Sulfonylurea daily dose (mg) 1.01 (0.97-1.06) 0.57
TCF7L2 genotype (rs7903146; per
allele effect)
1.57 (1.01-2.45) 0.046
TCF7L2 genotype (CC vs. TT) 2.09 (1.02-4.27) 0.043
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12 and 36 months of treatment, respectively [18,19].
The decreasing effectiveness of SUs results from pro-
gressive loss of b-cell function but also from patient
related factors (dietary incompliance, weight gain, lack
of exercise). Despite the above mentioned differences
between the studies, frequencies of TT homozygous
subjects in the groups of patients who failed to respond
to the therapy (independent of definition) were signifi-
cantly higher than in the control groups and were com-
parable between both studies (12% vs. 8% in the
German patients and 16% vs. 8% in the GoDARTS
study). Also, genotype distribution of the rs7903146 was
similar, with 10% and 11% of diabetic population with 2
copies of the T-allele in our study and the GoDARTS
study, respectively. Finally, similarly to the GoDARTS
study, our data suggest that carriers of the T allele were
57% more likely to fail SU treatment; TT homozygotes
were twice as likely as CC homozygotes.
It is noteworthy that an alternate definition of SU
treatment failure in our cohort based on addition of
insulin after at least 6 months of SU therapy and corre-
sponding A1C measurement of ≥7.0% yielded similar
results. Even though not independent from the previous
analyses, these findings provide further support for the
role of TCF7L2 genotypes in altered hypoglycaemic
response to SUs. Interestingly, when using this defini-
tion of SU treatment failure, diabetes duration appeared
to be a predictor of treatment failure along with the
TCF7L2 genotype. Nevertheless, the genotype effect was
independent as even after adjustment for diabetes dura-
tion, the results remained materially unchanged.
Although the P-value went from 0.04 to 0.06 the odds
ratio reduced only minimally (from 1.73 to 1.66).
Indirectly, our findings also support studies that
f a v o u rt h er o l eo fTCF7L2 in the regulation of insulin
secretion. However, we are aware that since the TCF7L2
variants increase progression from IGT to diabetes [5],
additional models considering diabetes therapy, particu-
larly including a control group having been treated with
a different antidiabetic agent - e.g., metformin, would be
desirable to clarify whether the observed data reflect
pharmacogenetic effects specific to SUs or rather a
disease-genetic process. Indeed, such a control group
treated with metformin was included in the GoDARTS
study [15]. The study suggested pharmacogenetic effects
of TCF7L2 SNPs influencing therapeutic response to
sulfonylureas but not metformin, since no association
was seen between metformin response and TCF7L2 var-
iants [15]. Even though limited by the small sample size
(N = 72), we also failed to observe any influence of
TCF7L2 genotypes on the response to metformin, as a
non-insulin secretagogue, thus further supporting the
notion that TCF7L2 effect is specific to the mechanism
of action of SUs.
One of the major limitations of our study is the low
sample size and so, limited statistical power. Taking into
account genotype frequencies and the sample size in
our study we had a statistical power of 80% (at a =
0.05) to detect genetic risk (odds ratio) of 1.8 for treat-
ment failure in additive mode of inheritance (software
Quanto version 1.2.2) [20]. In contrast, the GoDARTS
s t u d yb yP e a r s o ne tal. [15] had 80% power to detect
risk (OR) as low as 1.3. Also noteworthy, given the
TCF7L2 diabetes risk genotypes make patients more
resistant to the action of sulfonylureas, one would
expect that carriers of the risk genotype should be less
likely to become hypoglycaemic. However, in our study
we could not observe any differences in the frequency of
the diabetes risk allele between patients with and with-
out hypoglycaemia (P = 0.30).
Conclusion
In conclusion, present data strengthen previously
reported findings suggesting altered therapeutic
response to SUs in patients with T2D carrying the dia-
betes risk alleles at TCF7L2 variants.
Acknowledgements
This work was supported by grants from the Deutsche
Forschungsgemeinschaft (KFO-152 “Atherobesity” to AK (KO3512/1-1) and
DHFD to MS, PK). We would like to thank Ines Müller and Beate Enigk for
their excellent technical assistance.
Author details
1First Department of Medicine, Clinic Lippe-Detmold, Detmold, Germany.
2University Hospital for Children and Adolescents, University of Leipzig,
Table 3 Effect of rs7903146 genotype on sulfonylurea treatment failure under logistic regression analysis
Genotype rs7903146 Total Controls
(A1C <7%)
Failure of treatment with sulfonylurea
(A1C≥7%)
Frequency of T-allele
(controls vs. treatment failure)
Additive
P value
OR (95% CI)
n = 188 n = 91 n = 97
CC 91 (48.4%) 51 (56.0%) 40 (41.2%)
CT 78 (41.5%) 33 (36.3%) 45 (46.4%) 0.26/0.36 0.046
1.57 (1.01-2.45)
TT 19 (10.1%) 7 (7.7%) 12 (12.4%)
Holstein et al. BMC Medical Genetics 2011, 12:30
http://www.biomedcentral.com/1471-2350/12/30
Page 4 of 5Leipzig, Germany.
3Department of Medicine, University of Leipzig, Leipzig,
Germany.
4Interdisciplinary Centre for Clinical Research, University of Leipzig,
Leipzig, Germany.
Authors’ contributions
MH was responsible for clinical characteristics of study subjects. AK and MS
edited the manuscript and contributed to the discussion. AH and PK
conceived and designed the study and wrote the manuscript. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 October 2010 Accepted: 24 February 2011
Published: 24 February 2011
References
1. Clatworthy JP, Subramanian V: Stem cells and the regulation of
proliferation, differentiation and patterning in the intestinal epithelium:
emerging insights from gene expression patterns, transgenic and gene
ablation studies. Mechanisms of Development 2001, 101:3-9.
2. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A,
Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A,
Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T,
Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP,
Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G,
Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K: Variant of
transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2
diabetes. Nat Genet 2006, 38:320-323.
3. Zeggini E, McCarthy MI: TCF7L2: the biggest story in diabetes genetics
since HLA? Diabetologia 2007, 50:1-4.
4. Cauchi S, El Achhab YE, Choquet H, Dina C, Krempler F, Weitgasser R,
Nejjari C, Patsch W, Chikri M, Meyre D, Froguel P: TCF7L2 is reproducibly
associated with type 2 diabetes in various ethnic groups: a global meta-
analysis. J Mol Med 2007, 85:777-782.
5. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR,
Knowler WC, Nathan DM, Altshuler D: TCF7L2 polymorphisms and
progression to diabetes in the Diabetes Prevention Program. N Engl J
Med 2006, 355:241-250.
6. Kimber CH, Doney AS, Pearson ER, McCarthy MI, Hattersley AT, Leese GP,
Morris AD, Palmer CN: TCF7L2 in the Go-DARTS study: evidence for a
gene dose effect on both diabetes susceptibility and control of glucose
levels. Diabetologia 2007, 50:1186-1191.
7. Körner A, Berndt J, Stumvoll M, Kiess W, Kovacs P: TCF7L2 gene
polymorphisms confer an increased risk for early impairment of glucose
metabolism and increased height in obese children. J Clin Endocrinol
Metab 2007, 92:1956-1960.
8. Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD,
Shuldiner AR: Polymorphisms in the transcription factor 7-like 2 (TCF7L2)
gene are associated with type 2 diabetes in the Amish - Replication and
evidence for a role in both insulin secretion and insulin resistance.
Diabetes 2006, 55:2654-2659.
9. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M,
Florez JC, Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ,
Tuomi T, Hirschhorn JN, Ardlie KG, Groop LC, Altshuler D: Common single
nucleotide polymorphisms in TCF7L2 are reproducibly associated with
type 2 diabetes and reduce the insulin response to glucose in
nondiabetic individuals. Diabetes 2006, 55:2890-2895.
10. Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N,
Duren WL, Chines PS, Stringham HM, Erdos MR, Valle TT, Tuomilehto J,
Bergman RN, Mohlke KL, Collins FS, Boehnke M: Association of
transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a
Finnish sample. Diabetes 2006, 55:2649-2653.
11. Munoz J, Lok KH, Gower BA, Fernandez JR, Hunter GR, Lara-Castro C, De
Luca M, Garvey WT: Polymorphism in the transcription factor 7-like 2
(TCF7L2) gene is associated with reduced insulin secretion in
nondiabetic women. Diabetes 2006, 5:3630-3634.
12. Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B,
Charpentier G, Pattou F, Stetsyuk V, Scharfmann R, Staels B, Fruhbeck G,
Froguel P: Transcription factor TCF7L2 genetic study in the French
population - Expression in human beta-cells and adipose tissue and
strong association with type 2 diabetes. Diabetes 2006, 55:2903-2908.
13. Wang J, Kuusisto J, Vänttinen M, Kuulasmaa T, Lindström J, Tuomilehto J,
Uusitupa M, Laakso M: Variants of transcription factor 7-like 2 (TCF7L2)
gene predict conversion to type 2 diabetes in the Finnish Diabetes
Prevention Study and are associated with impaired glucose regulation
and impaired insulin secretion. Diabetologia 2007, 50:1192-1200.
14. Loos RJF, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, Ong KK,
O’Rahilly S, Wareham NJ: TCF7L2 polymorphisms modulate proinsulin
levels and beta-cell function in a British europid population. Diabetes
2007, 56:1943-1947.
15. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI,
Hattersley AT, Morris AD, Palmer CN: Variation in TCF7L2 influences
therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 2007,
56:2178-2182.
16. Gong MN: Gene association studies in acute lung injury: replication and
future direction. Am J Physiol 2009, 296:L711-L712.
17. Holstein A, Hahn M, Stumvoll M, Kovacs P: The E23K variant of KCNJ11
and the risk for severe sulfonylurea-induced hypoglycemia in patients
with type 2 diabetes. Horm Metab Res 2009, 41:387-390.
18. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J: Utilization of oral
hypoglycemic agents in a drug-insured US population. Diab Care 2001,
24:1411-1415.
19. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet,
sulfonylurea, metformin, or insulin in patients with type 2 diabetes
mellitus: progressive requirement for multiple therapies (UKPDS 49). UK
Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
20. Gauderman WJ, Morrison JM: QUANTO 1.1: A computer program for
power and sample size calculations for genetic-epidemiology studies.
2006 [http://hydra.usc.edu/gxe].
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/30/prepub
doi:10.1186/1471-2350-12-30
Cite this article as: Holstein et al.: TCF7L2 and therapeutic response to
sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics
2011 12:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Holstein et al. BMC Medical Genetics 2011, 12:30
http://www.biomedcentral.com/1471-2350/12/30
Page 5 of 5